EVX2

Across TCGA pan-cancer cohorts, EVX2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated EVX2 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher EVX2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EVX2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

THYM, ESCA, and BRCA are the cancer types where EVX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
ESCA	OS	Median	All	0.176	0.704	<.001	30	view →
BRCA	OS	Median	All	0.120	0.578	.004	22	view →
KIRC	OS	Median	All	0.182	0.805	.003	15	view →
LIHC	OS	Median	II,III,IV	0.094	0.696	<.001	12	view →
CESC	OS	Median	All	0.616	0.874	.035	6	view →
UCEC	DFS	Median	All	1.000	0.636	.044	2	view →
LUAD	DFS	Median	All	1.000	0.658	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

EVX2–THYM (OS)

Open the THYM breakdown →